Get started
Author

Douglas Cartwright

Observed names: Cartwright, Douglas, D Cartwright, D. Cartwright
Observed institutions: NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre, Cancer Research UK, Gartnavel General Hospital, Cancer Research UK Scotland Institute, Queen Elizabeth University Hospital, University of Glasgow
ORCID: 0000-0002-8780-6765
Observed ORCID: 0000-0002-8780-6765
OpenAlex ID: A5035813994
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 562
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 508
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 393
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 354
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 302
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 41
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy – Data supporting ‘Direct to LAT’ in selected groups
2019 · Selina Tsim, Sarah Paterson, et al. · Lung Cancer · 39
PDF
Omentum-derived matrix enables the study of metastatic ovarian cancer and stromal cell functions in a physiologically relevant environment
2023 · Lisa J. Neilson, Douglas Cartwright, et al. · Matrix Biology Plus · 10
Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting
2023 · Zena Alizzi, Patricia Roxburgh, et al. · Journal of Clinical Medicine · 10
PDF
Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?
2025 · Douglas Cartwright, Andrew C. Kidd, et al. · International Journal of Molecular Sciences · 9
PDF
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 6
First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis
2021 · Alistair McLaren, Douglas Cartwright, et al. · Journal of Immunotherapy and Precision Oncology · 6
PDF
Clinical Experience of Axillary Radiotherapy for Node-positive Breast Cancer
2023 · S. Anderson, A.L. Peters, et al. · Clinical Oncology · 2
Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the West of Scotland: a cohort study
2023 · Alistair Stewart McLaren, Johannes A Spoor, et al. · BMJ Open Gastroenterology · 2
PDF
1 Hyperglycaemia in T1DM and pancreatitis related diabetes
2020 · Omar Amin, Douglas Cartwright, et al. · Postgraduate Medical Journal · 2
1238eTiP Phase I/IIa, open-label, dose finding, safety and exploratory trial of THEO-260: A novel oncolytic immunotherapy, by intravenous delivery in patients with high grade serous or endometrioid ovarian cancer
2025 · M. Saggese, P. Roxburgh, et al. · Annals of Oncology · 1
109P Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer: The west of Scotland experience
2025 · N.C. Ramchander, D. Cartwright, et al. · Annals of Oncology · 1
PDF
Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective
2024 · A.L. Peters, P.S. Hall, et al. · The Breast · 1
Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers
2022 · D. Cartwright, M. White, et al. · ESMO Open · 1
510 Niraparib outcomes in brca wild-type platinum sensitive recurrent ovarian cancer: a comparison of real-world data to the nova trial
2020 · Douglas Cartwright, Patricia Roxburgh, et al. · International Journal of Gynecological Cancer · 1
PDF
Relapse Frequency and Pattern Following Adjuvant Radiotherapy for Intermediate and High-Intermediate Risk Endometrial Cancer Based on Retrospective ESGO-ESTRO-ESP Risk Classification
2025 · Kathryn Graham, Laura Hannington, et al. · Clinical and Experimental Obstetrics & Gynecology
Regional nodal irradiation for node-positive breast cancer
2022 · Adam Peters, Stephanie Anderson, et al. · Clinical Oncology
82P Clinical application of a genomic tool for decision support in breast cancer patients in Scotland
2022 · A.L. Peters, B. Elseberger, et al. · Annals of Oncology
PDF
Steroid receptor positivity and tumour type are influencing Oncotype DX recurrence score and subsequent treatment delivery in Scotland
2022 · Adam Peters, Husam Marashi, et al. · European Journal of Surgical Oncology
Works count: 33
Citation count: 2,292
H-index: 10
I10-index: 10
Year
Topic
Type